Lymphatic filariasis
Finding a cure to end a disabling disease
We are working to develop a safe, effective, field-adapted treatment to help eliminate lymphatic filariasis.
Also known as elephantiasis due to the extreme swelling (lymphoedema) that can result from the disease, lymphatic filariasis is caused by parasitic worms spread by the bites of infected mosquitoes. While people of all ages can get the disease, its most severe effects are only seen years after infection – and can result in abnormal enlargement of body parts, pain, severe disability, and social stigma.
Mass drug administration repeated over many years reduces transmission of the disease, but these treatments do not kill adult worms or reverse the long-term effects of infection.
India has committed to eliminating lymphatic filariasis by 2027 – and new treatments that kill both adult and juvenile worms could help the country achieve and sustain elimination.
‘I suffer from really painful attacks from the swelling in my legs.’
What we have achieved
Progress in the development of a macrofilaricide drug (a treatment able to kill adult worms) could benefit all filarial diseases. After testing oxfendazole for river blindness and other filarial diseases as part of the eWHORM consortium, DNDi is now supporting partners testing the drug against lymphatic filariasis.
What we are doing for people with lymphatic filariasis
We aim to test and develop a new treatment that can prevent disability and help eliminate lymphatic filariasis as a public health problem.
We are working with the Indian Council of Medical Research to test oxfendazole as a potential treatment for lymphatic filariasis. Already being tested against other helminth infections, oxfendazole could transform LF treatment if proven effective, and boost efforts to eliminate the disease in India.
Ivermectin is a critical drug against parasitic worm diseases – but a lack of data and suitable paediatric formulation leave it out of reach of children who need it. We are working with partners to develop and test a safe, child-friendly formulation of ivermectin.
The Fusidic Acid Macrofilaricide Evaluation (FAME) project aims to evaluate fusidic acid as a potential short-course treatment for river blindness (known as onchocerciasis), particularly in regions co-endemic with Loa loa (African eye worm), where treatment with ivermectin is contraindicated.
Lymphatic filariasis news & resources
Making medical history for neglected patients
We develop urgently needed treatments for neglected patients and ensure they’re affordable, available, and adapted to the communities who need them
Stay connected
Get our latest news, personal stories, research articles, and job opportunities.